Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. - Wikidata - wikimedia - TriplyDB

Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer.

Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q34883636

about

Splice Variants of Androgen Receptor and Prostate Cancer Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer Emerging data on androgen receptor splice variants in prostate cancer Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer.Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells.Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model.High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.RNA biomarkers to facilitate the identification of aggressive prostate cancer PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies Functional variants of the 5-methyltetrahydrofolate-homocysteine methyltransferase gene significantly increase susceptibility to prostate cancer: Results from an ethnic Han Chinese population MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai.Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells.Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.AR-v7 protein expression is regulated by protein kinase and phosphatase.Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells.A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance.Progress in the mechanism and drug development of castration-resistant prostate cancer.Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.Androgen receptor variation affects prostate cancer progression and drug resistance.Genomic tests to guide prostate cancer management following diagnosis.Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives.Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status.Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells.A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer Clinical relevance of androgen receptor alterations in prostate cancer.Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients.Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.

P2860

Q26740592-3509147C-71D9-44C2-BB3E-A30DB9C3FB6B Q28067556-B4CAEDB8-0C2B-4F96-B42F-ECC321FBF71D Q28077830-544883F2-DF49-4B8D-9F46-4F31412F4692 Q31046172-FF035118-CCE6-439C-BB2B-8C0173F3FAE1 Q33364957-1C21782E-4C36-49CB-AC33-B0FDF4BBC178 Q33821011-2AE5E14E-722C-4184-8ABB-233FFB4053F1 Q34464312-D65438F9-7B90-4E39-AB75-EA877B981411 Q35702322-B753A21B-AB24-45B2-A647-8847EF3B6F8A Q36152474-750956AC-4C96-47F1-BDA3-F433A66A13C1 Q36260364-87EC6A32-476F-42A5-BA1A-15B5E38DD610 Q37065079-1369C119-BF34-4260-B5A9-D4D493057CC0 Q37210010-9CD938DC-5824-4717-82E9-9FDD0DD754CC Q37390418-5E3CEA4B-0642-48EB-90DB-372EA60D6F68 Q37397446-9ADDAD57-ACD6-43F7-BCDC-000BD3956826 Q37550588-2454620C-DAB5-470A-9B7A-126E959562D4 Q37665251-59FA0A48-BC2B-4454-9349-778561807292 Q37737611-D0B282B2-7E34-4109-BAB8-B1CF9BBF7763 Q38261421-CB629371-CFE2-4386-A797-EDE29FFAB44C Q38697766-1B0C1BE2-1E24-4944-8743-97497BB248F4 Q38732922-F515415F-18B8-495D-9677-22D3C206DD3C Q38743584-2507571A-D3A1-48A2-A8B1-E19684386AA3 Q38826609-DC24A0CA-B4E4-4E21-B6B3-20F9909C8F86 Q38835693-A5C16305-E9F4-4DBC-BBC6-34ED58FBBBFE Q38848501-3F169266-0888-4522-9359-BC3D3A2381A7 Q38977288-24B34058-5613-426B-A7A7-CA584ED13C6E Q39170943-8063B98D-CC86-41E4-979B-99262BEB2D65 Q39215035-CFD0159F-35C5-4D00-9F1F-21848376B89D Q39285589-E7F1C450-D710-4B20-8A99-E201DEF219FD Q39341456-A9734620-05B4-42E6-853A-B7B9CD788F0D Q39819392-93FB1FFD-5121-4FF4-9CFE-D8F47E6EEB43 Q40355149-22324B43-5EB3-47D4-AD2C-783C34357D6D Q40423383-6BFE5B8D-EC06-43FE-B0A8-D994600FA1D6 Q41270542-CE7118EA-FA15-4148-9967-58111D1EB475 Q41488394-03BAD21C-8EFB-48FD-B81E-4ED11379505A Q41551014-F29B4F00-E5D0-4916-8F84-8878F4ACBEE7 Q42174990-2975AF11-3AF7-4FD4-BBAC-37A4F04CEFEA Q42377108-2E512975-EC5F-4B2C-AF79-2C6C23DB0CA0 Q42776456-BCF7F5A8-CF9C-4BCC-B232-DA06AA58E958 Q46233223-3638F6D1-294D-4B79-97AA-9EB916ECCC4B Q47155330-DD9F239C-2F14-4B52-87E7-F027F8FB34C6

P2860

Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q34883636

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Constitutively active AR-V7 pl ...... ion-resistant prostate cancer.

@ast

Constitutively active AR-V7 pl ...... ion-resistant prostate cancer.

@en

Constitutively active AR-V7 pl ...... ion-resistant prostate cancer.

@nl

type

label

Constitutively active AR-V7 pl ...... ion-resistant prostate cancer.

@ast

Constitutively active AR-V7 pl ...... ion-resistant prostate cancer.

@en

Constitutively active AR-V7 pl ...... ion-resistant prostate cancer.

@nl

prefLabel

Constitutively active AR-V7 pl ...... ion-resistant prostate cancer.

@ast

Constitutively active AR-V7 pl ...... ion-resistant prostate cancer.

@en

Constitutively active AR-V7 pl ...... ion-resistant prostate cancer.

@nl

P1433

Q34883636-8E3F052D-690C-4BEC-A075-95762A1118AE

P1476

Q34883636-A52821C4-AF49-4B9E-9EB1-887FBE2CEEE4

P2093

Q34883636-239F3634-6796-4C5F-9A75-B34662380C8C

Q34883636-246120A3-0D5E-428B-B38F-FE2AB2B7830A

Q34883636-2E713A2E-A0B2-4193-AB2A-363488F58452

Q34883636-5419E147-55F0-4AC0-8AD4-E60750B1ACFC

Q34883636-8A69A56D-ABC2-4D1C-A514-5348DC99DBC7

Q34883636-938CCD84-BBCA-4A5B-AE8A-D08DBFD33BBB

Q34883636-E285C337-851A-41E7-AE68-DE0B179AB25F

Q34883636-EE27A648-EE3C-4048-BE71-097CDFA65ABE

Q34883636-F299D828-BC5F-4AB0-9D06-52418D3C5A4E

P2860

Q34883636-1EBFA260-9601-4895-9D8F-E49144104607

Q34883636-2499117C-C21A-4B02-A610-9F67E3EA9706

Q34883636-28177F3A-526C-4ABE-B94D-6457FF141887

Q34883636-2C933EB7-3858-499B-B353-320F0A496A7B

Q34883636-442094A9-F5D0-4825-B602-5C7033F9A4A5

Q34883636-485F998B-0EB2-4E3C-B09B-AF339E5F08C9

Q34883636-53DD67A2-087C-4C31-8D3B-E1BBC91464DB

Q34883636-64C0727C-1815-43F6-9384-B6D2117BBA1F

Q34883636-6D82DA4C-6DC0-4C6D-9197-3C8E957C2A58

Q34883636-6DB3D62D-170F-4EAB-A81E-08C20B0132F4

P2888

Q34883636-FAD600BD-4517-4B51-9250-6F2F1CD71638

P304

Q34883636-87259832-6DD5-42AD-AE2D-07B26317BA5B

P31

Q34883636-2D27699B-3C74-415A-BD40-00FF7F6AA7C4

P356

Q34883636-51D3515A-89A2-4580-A1FB-CE84EFC02D2B

P407

Q34883636-9CF6D43C-E96C-45D6-81C8-ABF290A79259

P478

Q34883636-D77E460C-1C53-4660-8881-1A8D192F109B

P50

Q34883636-2F839840-6BFC-4F36-BE3B-5486646A14EC

P577

Q34883636-0B3671AE-DD9B-4FD9-ABF7-AC3C5DA47AAC

P5875

Q34883636-8E5F8AE7-D2C2-4694-AD22-882C2970FD06

P6179

Q34883636-475A332A-AA93-4BEA-AA1C-F239C74DC246

P698

Q34883636-5F9CA5F0-1A93-4607-AA10-D8F234F2E4DD

P932

Q34883636-025E721B-F927-4038-8F23-D6EA5FD4CB2E

P356

P1433

Scientific Reports

P1476

Constitutively active AR-V7 pl ...... ion-resistant prostate cancer.

@en

P2093

Bo Dai

http://www.w3.org/2001/XMLSchema#string

Dingwei Ye

http://www.w3.org/2001/XMLSchema#string

Guohai Shi

http://www.w3.org/2001/XMLSchema#string

Hailiang Zhang

http://www.w3.org/2001/XMLSchema#string

Kun Chang

http://www.w3.org/2001/XMLSchema#string

Xiaoqun Yang

http://www.w3.org/2001/XMLSchema#string

Yuanyuan Qu

http://www.w3.org/2001/XMLSchema#string

Yunyi Kong

http://www.w3.org/2001/XMLSchema#string

Zhongwei Jia

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.

Molecular biology of the androgen receptor.

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death

Estimates of the cancer incidence and mortality in Europe in 2006.

P2888

P304

7654

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP07654

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270654231

http://www.w3.org/2001/XMLSchema#string

P6179

1014573018

http://www.w3.org/2001/XMLSchema#string

P698

25563505

http://www.w3.org/2001/XMLSchema#string

P932

4288210

http://www.w3.org/2001/XMLSchema#string